Alecensa, an experimental drug by Genentech has been greenlighted by the US Food and Drug Administration because it has been found to cure non-small lung cancer in patients.
A study conducted by U.S. drug firm Merck found that administering Keytruda to patients with advanced stages of lung cancer significantly improved their chances of survival.
The rates at which nonsmokers get lung cancer have increased by up to 15 percent.
